S&P 500
7,663.43
-93.74
-1.21%
Dow
52,867.98
+11.89
+0.02%
Nasdaq
26,008.86
-694.00
-2.60%
NYSE Composite
24,275.53
+22.41
+0.09%
Russell 2000
2,784.03
+3.01
+0.11%
VIX
19.03
+2.35
+14.09%
COGT · Cogent Biosciences, Inc.
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
Cogent Biosciences Inc (COGT)
NASDAQ NMS - GLOBAL MARKET
Biotechnology
$31.32
-0.12
(-0.38%)
● At close: October 22 at 4:00:00 PM EDT
DAY'S RANGE
$31.32
$30.88
$31.66
52-WEEK RANGE
$31.32
$13.78
$43.73
What's happening
- COGT is down 0.38% today, trading at $31.32. — Live quote
- Volume today (90,806) is well below its 3-month average of 2,290,430. (Finnhub fundamentals)
- Reports earnings on 2026-11-10, 18 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-0.52 actual vs. $-0.58 estimated (+10.5%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 8
Buy 8
Hold 2
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (18 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
COGT
-11.51%
vs S&P 500
-24.88%
1-YEAR RETURN
COGT
+98.17%
vs S&P 500
+83.01%
6-MONTH RETURN
COGT
-15.62%
3-MONTH RETURN
COGT
-20.51%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.52
Est. $-0.58
BEAT +10.5%
2026-04-26 (Q1 2026)
$-0.60
Est. $-0.55
MISS -8.8%
2026-01-26 (Q4 2025)
$-0.64
Est. $-0.53
MISS -20.9%
2025-10-26 (Q3 2025)
$-0.50
Est. $-0.54
BEAT +7.1%
Valuation Measures & Ratios
Enterprise Value4$5.48B
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)234.74
Price / Book712.42
EV4 / Revenue236.56
EV4 / EBITDA—
Profit Margin-264.08%
Operating Margin-295.77%
Return on Equity (ROE8)-72.57%
Return on Assets (ROA9)-48.65%
Avg Volume (3M)2,290,430
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $7.18B | $7.07B | $2.32B | $999.6M | $827.8M |
| P/E | -20.61 | -21.84 | -7.82 | -3.63 | -3.19 |
| Price/Book | 13.48 | 11.64 | 7.68 | 6.45 | 3.78 |
| ROE | -65.41% | -53.28% | -98.22% | -177.44% | -118.69% |
| ROA | -41.73% | -35.86% | -69.75% | -100.10% | -91.59% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short19,462,718
Change from Prior Settlement+7.37%
% of Float—
Days to Cover (Short Ratio)8.08
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Trailing 52-week price return is +98.2%. Finnhub market metrics ↗
Potential concerns
- Net profit margin is -264.1%. Finnhub fundamentals ↗
- Latest SEC filing is Form 4, filed 2026-10-05; review it for current changes and risks. SEC EDGAR ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on COGT
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Operating income | -$102.6M | -$103.6M | -$83.4M | -$75.6M | -$74.9M | -$75.4M | -$64.4M | -$62.4M |
| Net income | -$96.4M | -$97.4M | -$80.9M | -$73.5M | -$72.0M | -$70.6M | -$59.0M | -$58.3M |
| EPS (diluted) | $-0.52 | $-0.53 | $-0.50 | $-0.53 | $-0.52 | $-0.52 | $-0.43 | $-0.49 |
| EPS (basic) | $-0.52 | $-0.53 | $-0.50 | $-0.53 | $-0.52 | $-0.52 | $-0.43 | $-0.49 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $834.5M | $903.0M | $937.6M | $425.9M | $274.8M | $283.8M | $327.9M | $384.0M |
| Total liabilities | $302.2M | $295.3M | $301.2M | $123.5M | $119.8M | $64.8M | $71.6M | $69.4M |
| Stockholders' equity | $532.4M | $607.7M | $636.4M | $302.5M | $155.0M | $219.0M | $256.3M | $314.7M |
| Total current assets | $804.8M | $877.8M | $910.4M | $397.2M | $245.0M | $252.9M | $296.5M | $341.5M |
| Total current liabilities | $59.3M | $58.0M | $64.0M | $62.2M | $58.4M | $49.3M | $55.7M | $53.0M |
| Cash & equivalents | $181.2M | $241.2M | $312.0M | $125.3M | $127.6M | $126.0M | $98.2M | $97.0M |
| Marketable securities (current) | — | — | — | — | — | — | — | — |
| Accounts receivable | — | — | — | — | — | — | — | — |
| Property, plant & equipment | $4.8M | $5.3M | $5.5M | $5.3M | $5.8M | $6.5M | $6.5M | $7.0M |
| Other non-current assets | $1.9M | $1.9M | $3.3M | $4.5M | $4.9M | $4.9M | $4.9M | $4.9M |
| Accounts payable | $7.5M | $13.7M | $9.5M | $16.0M | $16.6M | $14.2M | $12.0M | $15.1M |
| Deferred revenue (current) | — | — | — | — | — | — | — | — |
| Long-term debt | $223.5M | $223.2M | $222.9M | $44.2M | $43.9M | — | — | — |
| Other non-current liabilities | $90.0K | $62.0K | $33.0K | $2.4M | $2.4M | $5.0K | $0 | — |
| Common stock & paid-in capital | $171.0K | $171.0K | $161.0K | $141.0K | $114.0K | $114.0K | $110.0K | $110.0K |
| Retained earnings | -$1.38B | -$1.29B | -$1.19B | -$1.09B | -$1.00B | -$931.5M | -$859.5M | -$791.6M |
| Accumulated other comprehensive income (loss) | -$770.0K | -$415.0K | $355.0K | $208.0K | $13.0K | $164.0K | $447.0K | $896.0K |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$77.3M | -$86.9M | -$79.1M | -$64.3M | -$54.5M | -$66.5M | -$60.6M | -$52.0M |
| Investing cash flow | $14.3M | -$36.5M | -$322.8M | -$155.0M | $8.9M | $69.4M | $61.7M | $60.2M |
| Financing cash flow | $3.0M | $52.5M | $588.7M | $217.4M | $47.2M | $25.0M | $26.0K | $624.0K |
| Free cash flow | -$77.6M | -$87.3M | -$79.9M | -$64.4M | -$54.7M | -$67.1M | -$60.7M | -$52.3M |
| Capital expenditures | $370.0K | $449.0K | $811.0K | $65.0K | $131.0K | $547.0K | $75.0K | $280.0K |
| Share-based compensation | $17.1M | $16.9M | $15.8M | $10.6M | $9.7M | $10.0M | $10.0M | $10.4M |
| Deferred income taxes | — | — | $0 | — | — | — | $0 | — |
| Change in accounts receivable | — | — | — | — | — | — | — | — |
| Change in accounts payable | -$6.3M | $4.2M | -$6.5M | -$596.0K | $2.5M | $2.1M | -$3.0M | $6.1M |
| Purchases of investments | $82.8M | $133.8M | $395.2M | $224.1M | $67.9M | $0 | $12.7M | $19.5M |
| Debt issued | $0 | — | $0 | $0 | $49.3M | — | $0 | — |
| Tax withholding on stock comp | — | — | $48.9M | — | — | — | $0 | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating income | -$333.4M | -$275.9M | -$208.1M | -$147.8M | -$75.6M |
| Net income | -$328.9M | -$255.9M | -$192.4M | -$140.2M | -$72.3M |
| EPS (diluted) | $-2.16 | $-1.94 | $-1.94 | $-1.73 | $-1.87 |
| EPS (basic) | $-2.16 | $-1.94 | $-1.94 | $-1.73 | $-1.87 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $937.6M | $327.9M | $313.4M | $300.8M | $232.1M |
| Total liabilities | $301.2M | $71.6M | $55.6M | $45.1M | $17.9M |
| Stockholders' equity | $636.4M | $256.3M | $257.8M | $255.7M | $214.2M |
| Total current assets | $910.4M | $296.5M | $270.8M | $265.0M | $222.6M |
| Total current liabilities | $64.0M | $55.7M | $38.2M | $26.8M | $17.1M |
| Cash & equivalents | $312.0M | $98.2M | $53.2M | $139.9M | $219.7M |
| Accounts receivable | — | — | — | — | — |
| Property, plant & equipment | $5.5M | $6.5M | $8.3M | $7.8M | $1.7M |
| Other non-current assets | $3.3M | $4.9M | $4.9M | $4.7M | $3.7M |
| Accounts payable | $9.5M | $12.0M | $10.7M | $5.8M | $3.5M |
| Deferred revenue (current) | — | — | — | — | — |
| Long-term debt | $222.9M | — | — | — | — |
| Other non-current liabilities | $33.0K | $0 | — | — | — |
| Common stock & paid-in capital | $161.0K | $110.0K | $86.0K | $70.0K | $44.0K |
| Retained earnings | -$1.19B | -$859.5M | -$603.6M | -$411.2M | -$271.0M |
| Accumulated other comprehensive income (loss) | $355.0K | $447.0K | $246.0K | -$104.0K | — |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$264.4M | -$207.8M | -$153.6M | -$118.6M | -$58.8M |
| Investing cash flow | -$399.5M | $38.3M | -$97.8M | -$124.7M | -$1.7M |
| Financing cash flow | $878.2M | $214.5M | $163.5M | $163.6M | $38.0M |
| Free cash flow | -$266.0M | -$208.4M | -$156.4M | -$125.5M | -$60.5M |
| Capital expenditures | $1.6M | $573.0K | $2.8M | $6.9M | $1.7M |
| Share-based compensation | $46.1M | $39.7M | $30.6M | $18.4M | $11.7M |
| Deferred income taxes | $0 | $0 | $0 | $0 | $0 |
| Change in accounts receivable | — | — | — | — | — |
| Change in accounts payable | -$2.5M | $1.4M | $4.8M | $2.4M | $2.8M |
| Purchases of investments | $687.2M | $255.6M | $348.8M | $177.9M | $0 |
| Debt issued | $49.3M | $0 | $0 | — | — |
| Tax withholding on stock comp | $48.9M | $0 | $0 | — | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding COGT as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2025-12-17 to 2026-08-27
Recent transactions
- Insiders have net sold 45,510 shares over the last 182 days, across 0 purchases and 2 sales.
- Most recent: Morris Arlene (Reporting person) — Option exercise of 41,927 shares on 2026-08-27.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)45,510 sh(2 txns)
Net Shares-45,510
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Morris Arlene | Reporting person | Option exercise | 2026-08-27 | 41,927 |
| Robbins Andrew R | President and CEO | Gift | 2026-05-19 | 160,000 |
| Fairmount Funds Management LLC | Director | Derivative conversion | 2026-03-31 | 7,000,000 |
| Kearns Evan | Chief Legal Officer | Open market sale | 2025-12-26 | 65,000 |
| Green John L. | Chief Financial Officer | Open market sale | 2025-12-26 | 77,000 |
| Sachs Jessica | Chief Medical Officer | Open market sale | 2025-12-26 | 82,642 |
| Robinson John Edward | Chief Scientific Officer | Open market sale | 2025-12-26 | 90,000 |
| Pinnow Cole | Chief Commercial Officer | Grant / award | 2025-12-17 | 50,000 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-08-27 | Morris Arlene | Reporting person | Option exercise | 41,927 | $5.64 |
| 2026-08-27 | Morris Arlene | Reporting person | Option exercise | 3,583 | $2.52 |
| 2026-08-27 | Morris Arlene | Reporting person | Open market sale | 42,349 | $37.09 |
| 2026-08-27 | Morris Arlene | Reporting person | Open market sale | 3,161 | $37.54 |
| 2026-05-19 | Robbins Andrew R | President and CEO | Gift | 160,000 | $0.00 |
| 2026-05-19 | Robbins Andrew R | President and CEO | Gift | 160,000 | $0.00 |
| 2026-03-31 | Fairmount Funds Management LLC | Director | Derivative conversion | 7,000,000 | — |
| 2026-03-31 | Fairmount Funds Management LLC | Director | Open market sale | 7,000,000 | $34.66 |
| 2026-01-22 | Fairmount Funds Management LLC | Director | Open market sale | 3,500,000 | $36.40 |
| 2025-12-26 | Kearns Evan | Chief Legal Officer | Open market sale | 65,000 | $38.70 |
| 2025-12-26 | Green John L. | Chief Financial Officer | Open market sale | 77,000 | $38.68 |
| 2025-12-26 | Sachs Jessica | Chief Medical Officer | Open market sale | 82,642 | $38.70 |
| 2025-12-26 | Robinson John Edward | Chief Scientific Officer | Open market sale | 90,000 | $38.74 |
| 2025-12-17 | Robinson John Edward | Chief Scientific Officer | Grant / award | 50,000 | $0.00 |
| 2025-12-17 | Robinson John Edward | Chief Scientific Officer | Grant / award | 320,000 | $0.00 |
| 2025-12-17 | Robinson John Edward | Chief Scientific Officer | Tax withholding | 139,998 | $39.45 |
| 2025-12-17 | Robbins Andrew R | President and CEO | Grant / award | 185,000 | $0.00 |
| 2025-12-17 | Robbins Andrew R | President and CEO | Grant / award | 840,000 | $0.00 |
| 2025-12-17 | Robbins Andrew R | President and CEO | Tax withholding | 367,497 | $39.45 |
| 2025-12-17 | Pinnow Cole | Chief Commercial Officer | Grant / award | 50,000 | $0.00 |
| 2025-12-17 | Pinnow Cole | Chief Commercial Officer | Grant / award | 214,000 | $0.00 |
| 2025-12-17 | Pinnow Cole | Chief Commercial Officer | Tax withholding | 94,800 | $39.45 |
| 2025-12-17 | Kearns Evan | Chief Legal Officer | Grant / award | 40,000 | $0.00 |
| 2025-12-17 | Kearns Evan | Chief Legal Officer | Grant / award | 260,000 | $0.00 |
| 2025-12-17 | Kearns Evan | Chief Legal Officer | Tax withholding | 125,602 | $39.45 |
| 2025-12-17 | Sachs Jessica | Chief Medical Officer | Grant / award | 50,000 | $0.00 |
| 2025-12-17 | Sachs Jessica | Chief Medical Officer | Grant / award | 320,000 | $0.00 |
| 2025-12-17 | Sachs Jessica | Chief Medical Officer | Tax withholding | 154,716 | $39.45 |
| 2025-12-17 | Green John L. | Chief Financial Officer | Grant / award | 50,000 | $0.00 |
| 2025-12-17 | Green John L. | Chief Financial Officer | Grant / award | 300,000 | $0.00 |
| 2025-12-17 | Green John L. | Chief Financial Officer | Tax withholding | 145,007 | $39.45 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-23 04:04 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-05 | 4 | 2026-10-01 | View on SEC.gov → |
| 2026-09-02 | 8-K | 2026-09-01 | View on SEC.gov → |
| 2026-08-31 | 4 | 2026-08-27 | View on SEC.gov → |
| 2026-08-10 | 8-K | 2026-08-10 | View on SEC.gov → |
| 2026-08-10 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-10 | 8-K | 2026-08-10 | View on SEC.gov → |
| 2026-07-06 | 4 | 2026-07-01 | View on SEC.gov → |
| 2026-06-11 | 4 | 2026-06-09 | View on SEC.gov → |
| 2026-06-11 | 4 | 2026-06-09 | View on SEC.gov → |
| 2026-06-11 | 4 | 2026-06-09 | View on SEC.gov → |
| 2026-06-11 | 4 | 2026-06-09 | View on SEC.gov → |
| 2026-06-11 | 4 | 2026-06-09 | View on SEC.gov → |
Recent news
Headlines about COGT (Cogent Biosciences, Inc.). Links open the publisher — we don’t host full articles.
-
If You Invested $1000 In Cogent Biosciences Stock 5 Years Ago, You Would Have This Much Today
Benzinga · 2026-10-21 -
Cogent Biosciences, Inc. (COGT) Stock Price, News, Quote & History
Yahoo! Finance Canada · 2026-10-21 -
Cogent Biosciences (COGT) Nears Three FDA Decisions. What Is Its Pipeline Worth?
Yahoo · 2026-10-20 -
COGT Nov 2026 38.000 call (COGT261120C00038000) Stock Price, News, Quote & History
Yahoo! Finance Canada · 2026-10-20 -
COGT Nov 2026 31.000 put (COGT261120P00031000) Stock Price, News, Quote & History
Yahoo! Finance Canada · 2026-10-20 -
Did FDA Filings Just Shift Cogent Biosciences Stock Investment Narrative?
Simply Wall Street · 2026-10-18 -
COGT Oct 2026 30.000 put (COGT261016P00030000) Interactive Stock Chart
Yahoo! Finance Canada · 2026-10-16 -
COGT Oct 2026 30.000 put (COGT261016P00030000) Stock Price, News, Quote & History
Yahoo! Finance Canada · 2026-10-16
No headlines in this category right now — try “All”.